Country: Canada
Language: English
Source: Health Canada
PALOVAROTENE
IPSEN BIOPHARMACEUTICALS CANADA INC
M09AX11
PALOVAROTENE
10MG
CAPSULE
PALOVAROTENE 10MG
ORAL
15G/50G
Prescription
Active ingredient group (AIG) number: 0163378005; AHFS:
APPROVED
2022-01-21
_SOHONOS_ _®_ _ (palovarotene capsule) _ _Page 1 of 46_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr SOHONOS ® palovarotene capsules Capsules, 1 mg, 1.5 mg, 2.5 mg, 5 mg, 10 mg, Oral Retinoid/Retinoic acid receptor gamma (RAR ) selective agonist Ipsen Biopharmaceuticals Canada Inc. 5050 Satellite Drive, Suite 500 Mississauga ON L4W 0G1 www.ipsen.ca Date of Initial Authorization: JAN 20, 2022 Date of Revision: NOV 17, 2023 Submission Control Number: 268140 SOHONOS is a registered trademark of Clementia Pharmaceuticals Inc. ©2021. All rights reserved. _ _ _SOHONOS_ _®_ _ (palovarotene capsule) _ _Page 2 of 46 _ RECENT MAJOR LABEL CHANGES 1 Indications 11/2023 3 Serious Warnings and Precautions 11/2023 4 Dosage and Administration 11/2023 7 Warnings and Precautions 11/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ...................................................................................... 2 TABLE OF CONTENTS ........................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ............................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics ............................................................................................................. 4 1.2 Geriatrics ............................................................................................................. 4 2 CONTRAINDICATIONS ................................................................................................ 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ...................................................... 4 4 DOSAGE AND ADMINISTRATION .............................................................................. 5 4.1 Dosing Considerations .................................................. Read the complete document